会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders
    • US20100152175A1
    • 2010-06-17
    • US12636849
    • 2009-12-14
    • Giuseppe AlvaroDaniele AndreottiSandro BelvedereRomano Di FabioAlessandro FalchiRiccardo Giovannini
    • Giuseppe AlvaroDaniele AndreottiSandro BelvedereRomano Di FabioAlessandro FalchiRiccardo Giovannini
    • A61K31/5383A61P25/30
    • C07D487/04C07D513/04
    • There are provided according to the invention novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein: X represents a nitrogen atom; Y represents —C(H2)—, (—C(H2)—)2, —S(O2)— or —C(═O)—; Z represents —C(H2)—, —S(O2)—, —N(Rz)—, or an oxygen or sulphur atom; A represents hydrogen or —CH2OH; Rz represents hydrogen, C1-6 alkyl, C1-6 alkoxy, —COR7 or —SO2R7; R1 represents halogen, C1-6 alkyl, C1-6 alkoxy, ═O, haloC1-6 alkyl, haloC1-6 alkoxy, hydroxyl or —CH2OH; m represents an integer from 0 to 3; R2 represents halogen, ═O, C1-6 alkyl (optionally substituted by one or more hydroxyl groups), —COOR7, —CONR7R8, C1-6 alkoxy, haloC1-6 alkyl, haloC1-6 alkoxy or C1-6alkylOC1-6alkyl; n represents an integer from 0 to 3; p and q independently represent an integer from 0 to 2; R3 represents an -aryl, -heteroaryl, -heterocyclyl, -aryl-aryl, -aryl-heteroaryl, -aryl-heterocyclyl, -heteroaryl-aryl, -heteroaryl-heteroaryl, -heteroaryl-heterocyclyl, -heterocyclyl-aryl, -heterocyclyl-heteroaryl or -heterocyclyl-heterocyclyl group, all of which may be optionally substituted by one or more (e.g. 1, 2 or 3) halogen, C1-6 alkyl (optionally substituted by one or more hydroxyl groups), C3-8 cycloalkyl, C1-6 alkoxy, hydroxyl, haloC1-6 alkyl, haloC1-6 alkoxy, cyano, —S—C1-6 alkyl, —SO—C1-6 alkyl, —SO2—C1-6 alkyl, —COR7, —CONR7R8, —NR7R8, —NR7COC1-6 alkyl, —NR7SO2—C1-6 alkyl, C1-6 alkyl-NR7R8, —OCONR7R8, —NR7CO2R8 or —SO2NR7R8 groups; R4 and R5 independently represent C1-6 alkyl, or R4 and R5 together with the carbon atom to which they are attached may together form a C3-8 cycloalkyl group; R6 represents halogen, C1-6 alkyl, C3-8 cycloalkyl, C1-6 alkoxy, haloC1-6 alkyl or haloC1-6 alkoxy; s represents an integer from 0 to 4; R7 and R8 independently represent hydrogen, C1-6 alkyl or C3-8 cycloalkyl; or solvates thereof.
    • 6. 发明申请
    • Condensed n-heterocyclic compounds and their use as crf receptor antagonists
    • 缩合的N-杂环化合物及其作为crf受体拮抗剂的用途
    • US20070004708A1
    • 2007-01-04
    • US10552493
    • 2004-04-07
    • Daniele AndreottiGiovannie BernasconiEmiliano CastiglioniStefania ContiniRomano Di FabioElettra FazzolariAldo FerianiGabriella GentileMario MattioliAnna MingardiFabio SabbatiniYves St-Denis
    • Daniele AndreottiGiovannie BernasconiEmiliano CastiglioniStefania ContiniRomano Di FabioElettra FazzolariAldo FerianiGabriella GentileMario MattioliAnna MingardiFabio SabbatiniYves St-Denis
    • A61K31/549A61K31/519A61K31/496A61K31/501A61K31/4745C07D487/02C07D471/02
    • C07D471/04C07D487/04
    • The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof (Formula (I)) wherein the dashed line may represent a double bond; R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 lkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, —C(O)R2, nitro, hydroxy, —NR3R4, cyano and or a group Z; R1 is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR3R4 or cyano; D, G is —C— optionally substituted; X is carbon or nitrogen; Y is nitrogen or —C— optionally substituted; W is a 4-8 membered ring, which may be saturated or may contain one to three double bonds, and in which:—one carbon atom is replaced by a carbonyl or S(O)m; and—one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR12, S(O)m, carbonyl, and such ring may be further substituted by 1 to 8 substituents; Z is a 5-6 membered heterocycle, which may be substituted by 1 to 8 R5 groups or a phenyl ring, which may be substituted by 1 to 4 substituents; m is an integer from 0 to 2. to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).
    • 本发明提供了包含立体异构体,前体药物和药学上可接受的盐或溶剂合物(式(I))的式(I)化合物,其中虚线可以表示双键; R是芳基或杂芳基,其各自可以被1-4个选自以下的基团取代:卤素,C 1 -C 6烷基,C 1 -C 6烷氧基,卤代C 1 -C 6烷基,C 2 -C 6烯基,C 2 -C 6炔基,卤素 C 1 -C 6烷氧基,-C(O)R 2,硝基,羟基,-NR 3 R 4,氰基和/或Z ; R 1是氢,C 3 -C 7环烷基,C 1 -C 6烷基,C 1 -C 6烷氧基,C 1 -C 6硫代烷基,C 2 -C 6烯基,C 2 -C 6炔基,卤代C 1 -C 6烷基,卤代C 1 -C 6烷氧基,卤素,NR 3 R 4或氰基; D,G是-C-任选取代的; X是碳或氮; Y是氮或-C-任选取代的; W是4-8元环,其可以是饱和的或可以含有一至三个双键,并且其中: - 一个碳原子被羰基或S(O)m取代; 一至四个碳原子可以任选地被氧,氮或NR 12,S(O)m H,羰基取代,并且这种环可进一步被1 至8个取代基; Z是5-6元杂环,其可被1至8个R 5取代基或可被1至4个取代基取代的苯环; m为0至2的整数。其制备方法,含有它们的药物组合物及其用于治疗由促肾上腺皮质激素释放因子(CRF)介导的病症的用途。